Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biotechnology company focused on developing innovative therapies using RNA interference (RNAi) technology. This approach aims to silence specific genes that cause diseases, effectively "turning off" harmful proteins. Their treatments target various genetic disorders and conditions, including certain rare diseases. Alnylam's commitment to research and development has led to several groundbreaking medicines, making significant impacts on patient care. By leveraging cutting-edge science, the company aims to transform how we treat some of the most challenging genetic diseases.